Immunovant Reports Q1 FY2026 Results: $153M Net Loss, $798M Cash, Pipeline On Track
IMVT has more than doubled off its 52-week low of $14.32.
Summary
Immunovant posted a $153.2M net loss for Q1 FY2026, driven by higher R&D for IMVT-1402. Cash of $797.8M provides runway to the potential GD launch, and all six clinical programs remain on schedule.
Key Events · Earnings and Guidance · IMVT
-
Q1 FY2026 Net Loss Widens
Net loss of $153.2 million ($0.75/share) vs. $120.6 million ($0.71/share) a year ago, driven by a 41% increase in R&D expenses to $142.6 million for IMVT-1402 trials.
-
Cash Runway to GD Launch
Cash and equivalents of $797.8 million as of June 30, 2026, expected to fund operations through the potential commercial launch of IMVT-1402 in Graves' disease.
-
Pipeline On Track, Key Data in H2 2026
All six IMVT-1402 programs remain on schedule; topline data from the potentially registrational D2T RA program and proof-of-concept CLE trial expected in H2 2026.
-
R&D Spend Ramping, G&A Declining
R&D expenses rose to $142.6M from $101.2M, reflecting increased clinical trial and manufacturing costs; G&A fell to $17.7M from $26.0M on lower personnel and professional fees.
Analysis · IMVT · Life Sciences
Immunovant's first fiscal quarter results show a widening net loss to $153.2 million as R&D spending ramps for IMVT-1402 across six indications. The $797.8 million cash position is the key number — management says it funds operations through the potential Graves' disease launch, removing near-term financing risk. All clinical timelines are reaffirmed, with two data readouts expected in the second half of 2026. The stock is near its 52-week high, reflecting market optimism around the pipeline, but the rising cash burn rate and recent insider selling warrant attention.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IMVT was trading at $39.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.1B. The 52-week trading range was $14.32 to $41.23. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.